Gyre Therapeutics, Inc. (GYRE) fundamentals score
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. It operates through its majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through its U.S. operations headquartered in San Diego, California.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.7 out of 10, Weak long-term fundamentals
- Growth: 3.2/10
- Profitability: 2.8/10
- Financial health: 7.6/10
- Earnings quality: 5.7/10
- Valuation: 5.3/10
Scores are calculated from Gyre Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10